The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
Journal of Neuromuscular Diseases · 2023
DOI: 10.3233/jnd-221648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2023. Verfasst von Annemieke Aartsma-Rus und 9 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Dystrophin, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antisense oligonucleotide (ASO) mediated exon skipping aims to reframe dystrophin transcripts for patients with Duchenne muscular dystrophy (DMD). Currently 4 ASOs have been approved by the Food and Drug Administration targeting exon 45, 51 and 53 based on low level dystrophin restoration. Additional studies to confirm functional effects are ongoing. Furthermore, efforts are ongoing to increase muscle specific delivery of ASOs. Consequently, there are 5 clinical trials ongoing or planned for exon 51 skipping ASOs in Europe. While exon 51 skipping applies to the largest group of patients, DMD expert centers do not have sufficient numbers of patients or capacity to run all these trials in parallel. Even at a national level numbers may be too scarce. At the same time, some families now face the choice between participation in different clinical trials of exon 51 skipping, sometimes in addition to the choice of participating in a micro-dystrophin gene therapy trial. In this opinion paper, we outline the challenges, compare the different exon 51 skipping trials, and outline how different European centers and countries try to cope with running multiple trials in parallel for a small group of eligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leiden University Medical Center, Leiden, the Netherlands.
- Duchenne Center Netherlands, the Netherlands.
- Department of Paediatrics, University Hospitals Leuven, Leuven, Belgium.
- Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
- Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Amalia Children's Hospital, Nijmegen, the Netherlands.
- Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Zitieren
APA
Aartsma-Rus, A., De Waele, L., Houwen-Opstal, S., Kirschner, J., Krom, Y. D., Mercuri, E., Niks, E. H., Straub, V., van Duyvenvoorde, H. A., & Vroom, E. (2023). The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-221648
Vancouver
Aartsma-Rus A, De Waele L, Houwen-Opstal S, Kirschner J, Krom YD, Mercuri E, et al. The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience. Journal of Neuromuscular Diseases. 2023. doi:10.3233/jnd-221648
BibTeX
@article{AartsmaRus2023,
author = {Aartsma-Rus, Annemieke and De Waele, Liesbeth and Houwen-Opstal, Saskia and Kirschner, Janbernd and Krom, Yvonne D and Mercuri, Eugenio and Niks, Erik H and Straub, Volker and van Duyvenvoorde, Hermine A and Vroom, Elizabeth},
title = {The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience},
journal = {Journal of Neuromuscular Diseases},
year = {2023},
doi = {10.3233/jnd-221648}
}
EUVIMED